Welcome to our dedicated page for Biovie SEC filings (Ticker: BIVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioVie Inc. (NASDAQ: BIVI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical issuer, BioVie files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A, and registration statements such as Form S-1 related to securities offerings.
Through these filings, BioVie describes its clinical-stage programs in neurological and neurodegenerative disorders and advanced liver disease, including development of bezisterim (NE3107) for Alzheimer’s disease, Parkinson’s disease and long COVID, and BIV201, a continuous infusion terlipressin therapy for complications of advanced liver cirrhosis. Investors can review risk factors, clinical trial descriptions, regulatory designations such as Orphan Drug and Fast Track status for BIV201, and discussions of how neuroinflammation and insulin resistance are believed to relate to the company’s target indications.
Current reports on Form 8-K capture material events such as underwritten public offerings of units and warrants, the listing of warrants under the symbol BIVIW, the implementation of a one-for-ten reverse stock split, amendments to the 2019 Omnibus Equity Incentive Plan, and changes in the composition of the board of directors. Registration statements and their amendments detail the terms of securities being offered, including units, pre-funded warrants, and warrants, and provide additional narrative on BioVie’s business and clinical pipeline.
On Stock Titan, these SEC documents are presented with real-time updates from EDGAR and AI-powered summaries that help explain the key points of lengthy filings. Users can quickly identify items related to clinical trial progress, capital raising transactions, equity incentive plans, and corporate governance without reading every page. Forms 10-K and 10-Q can be reviewed with AI-generated highlights of segment information and risk disclosures, while Form 4 and related ownership filings, when available, can be used to monitor insider equity activity.
This centralized view of BioVie’s SEC filings allows investors and researchers to track how the company describes its neurology and liver disease programs, financing activities, and corporate actions over time, with AI tools to make complex regulatory language more accessible.
BioVie Inc. is a clinical-stage biotech reporting a net loss of about
The company ended the period with cash and cash equivalents of
BioVie is advancing bezisterim (NE3107) for Parkinson’s disease, long COVID and Alzheimer’s disease, and BIV201 for cirrhosis and ascites. A Phase 2b Parkinson’s study completed enrollment of 60 patients with topline data expected in the first half of 2026, and a DOD-funded long COVID Phase 2 trial is underway. The Alzheimer’s Phase 3 trial was left underpowered after excluding patients from sites with protocol and cGCP issues. The company also formed Option Therapeutics for a potential spin-off of its liver program and filed an S-1 for a possible IPO.
BioVie Inc. reported that Chief Medical Officer Joseph M. Palumbo received a grant of 132,000 stock options on January 5, 2026.
The options, held directly, have an exercise price of $1.31 per share, were granted at no cost, and are exercisable for 132,000 shares of common stock. According to the vesting schedule, 55% of the options vested on January 5, 2026, with the remaining options vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029. Any unexercised options expire on January 5, 2036.
BioVie Inc. reported that its Chief Financial Officer, Joanne Wendy Kim, received a grant of stock options on January 5, 2026. The award covers 110,100 stock options with an exercise price of $1.31 per share, giving her the right to buy BioVie common stock at that price in the future. The filing shows she directly holds all 110,100 options after this transaction.
According to the vesting schedule, 55% of the options vested on January 5, 2026, meaning more than half became exercisable immediately. The remaining options are set to vest in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029, aligning her long-term incentives with the company’s performance over several years.
BioVie Inc. director Sigmund Rogich reported new option grants. On January 5, 2026, he was awarded stock options covering 70,000 shares and an additional 141,100 shares of BioVie common stock, each with an exercise price of $1.31 per share.
The 70,000-share option grant vests in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 and the company’s 2026 annual shareholders’ meeting. For the 141,100-share grant, 75% vested on January 5, 2026, with the remaining options vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.
BioVie Inc. reported an insider equity award connected to its President & CEO, Cuong V Do. On January 5, 2026, Do & Rickles Investments LLC, an entity associated with him, was granted a stock option to buy 665,300 shares of BioVie common stock at an exercise price of $1.31 per share. The option was reported as an indirect holding.
According to the vesting terms, 55% of the options vested on January 5, 2026, with the remaining balance vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029. The filing shows a grant price of $0 for the derivative security itself, which reflects that this was an option award rather than an open‑market purchase.
BioVie Inc. director Michael Edward Sherman received new stock option awards. On January 5, 2026, he was granted stock options to purchase 80,000 shares of BioVie common stock at an exercise price of $1.31 per share, expiring on January 5, 2031. These options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the company’s 2026 annual shareholders’ meeting.
On the same date, he was also granted stock options to purchase 341,100 shares of common stock at the same $1.31 exercise price, also expiring on January 5, 2031. For this grant, 75% of the options vested on January 5, 2026, with the remaining 25% vesting in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. Both grants are reported as directly owned.
BioVie Inc. director Kameel D. Farag received a grant of 57,500 stock options on January 5, 2026. The options have an exercise price of $1.31 per share and, if not exercised, expire on January 5, 2031. Each option is exercisable for one share of BioVie common stock, giving Farag the right to buy up to 57,500 shares.
According to the vesting terms, 7,500 options vest on the grant date, while the remaining options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 and the company’s 2026 annual shareholders’ meeting. After this grant, Farag beneficially holds 57,500 derivative securities in the form of these stock options.
BioVie Inc. director Amy Suzon Chappell reported receiving a stock option grant on January 5, 2026. The award covers options to purchase 57,500 shares of BioVie common stock at an exercise price of $1.31 per share, with no cash paid for the grant itself.
According to the vesting terms, 7,500 shares underlying the options vest on the grant date. The remaining options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and on the earlier of November 11, 2026 and the date of BioVie’s 2026 annual shareholders’ meeting. The options expire on January 5, 2031 if not exercised.
BioVie Inc. director James Paul Lang reported new stock option awards. On January 5, 2026, he received two grants of stock options to buy BioVie common stock at an exercise price of $1.31 per share, one covering 90,000 shares and another covering 330,500 shares, both expiring on January 5, 2031.
The 90,000-share option vests in four equal installments on February 10, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of BioVie’s 2026 annual shareholders’ meeting. For the 330,500-share option, 75% vested on January 5, 2026, with the remaining portion vesting in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. Both awards are held directly by the director and were reported as acquisitions of derivative securities.
BioVie Inc. (BIVI) has filed a Form S-8 registration statement for its 2019 Omnibus Equity Incentive Plan, which has been amended and restated through November 10, 2025. This filing allows the company to register shares that may be issued to employees, directors and other service providers as equity-based compensation under the updated plan. The document also outlines Nevada law provisions that protect and indemnify directors and officers, and notes that BioVie may advance expenses and purchase insurance for them. The filing is signed by Chief Executive Officer Cuong Do and other senior leaders, confirming their authorization to submit amendments and related documents as needed.